ALK and non-small cell lung carcinoma: ALC, known by its brand name Alecensa®, has received approval from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its use as a first-line treatment in patients with ALK-positive metastatic non-small cell lung cancer (ALK+ NSCLC) who have developed resistance to crizotinib or whose disease has progressed despite treatment with crizotinib [8,9].